PDCD1 and neoplasm: Based on the original analysis included in this study, we believe that even when PD-1/PD-L1 checkpoint inhibitors were used as the third-, fourth-, or later lines of treatment, the occurrence of irCAEs still indicates better anti-tumour treatment efficacy if parameters such as ECOG status showed improvement.